Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings or view top-rated stocks.

1 analysts have issued 1 year price targets for Ironwood Pharmaceuticals' shares. Their IRWD share price forecasts range from $19.00 to $22.00. On average, they anticipate the company's stock price to reach $20.50 in the next year. This suggests a possible upside of 111.3% from the stock's current price.
View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts.

Ironwood Pharmaceuticals' stock was trading at $12.39 on January 1st, 2023. Since then, IRWD shares have decreased by 21.7% and is now trading at $9.70.
View the best growth stocks for 2023 here.

Ironwood Pharmaceuticals saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 14,660,000 shares, a decrease of 5.4% from the August 31st total of 15,500,000 shares. Based on an average trading volume of 2,420,000 shares, the short-interest ratio is presently 6.1 days. Currently, 9.6% of the shares of the stock are short sold.
View Ironwood Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IRWD earnings forecast.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.25 by $0.06. The biotechnology company had revenue of $107.38 million for the quarter, compared to the consensus estimate of $103.46 million. Ironwood Pharmaceuticals had a negative net margin of 214.68% and a positive trailing twelve-month return on equity of 55.17%.

ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ETC 6 Meridian Small Cap Equity ETF (SIXS), SPDR S&P Biotech ETF (XBI) and Pacer US Small Cap Cash Cows 100 ETF (CALF).

Ironwood Pharmaceuticals issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $435.00 million-$450.00 million, compared to the consensus revenue estimate of $427.88 million.

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRWD stock can currently be purchased for approximately $9.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.51 billion and generates $427.28 million in revenue each year. The biotechnology company earns $175.07 million in net income (profit) each year or ($6.04) on an earnings per share basis.

The company employs 219 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480.